{"protocolSection": {"identificationModule": {"nctId": "NCT01910441", "orgStudyIdInfo": {"id": "CLAF237AIN03"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients", "officialTitle": "A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone", "acronym": "VARIABLE"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "TERMINATED", "whyStopped": "The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-07"}, "primaryCompletionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-07-25", "studyFirstSubmitQcDate": "2013-07-25", "studyFirstPostDateStruct": {"date": "2013-07-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-09-22", "resultsFirstSubmitQcDate": "2015-09-22", "resultsFirstPostDateStruct": {"date": "2015-10-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-22", "lastUpdatePostDateStruct": {"date": "2015-10-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 Diabetes Mellitus, Glycemic variability"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 95, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group A: Vildagliptin plus metformin", "type": "EXPERIMENTAL", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).", "interventionNames": ["Drug: Vildagliptin", "Drug: Metformin"]}, {"label": "Group B: Glimepiride plus metformin", "type": "ACTIVE_COMPARATOR", "description": "Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).", "interventionNames": ["Drug: Glimepiride", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Vildagliptin", "description": "Vildagliptin 50 mg twice daily", "armGroupLabels": ["Group A: Vildagliptin plus metformin"]}, {"type": "DRUG", "name": "Glimepiride", "description": "Glimepiride 1-6 mg once daily", "armGroupLabels": ["Group B: Glimepiride plus metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin (1000-1500 mg daily)", "armGroupLabels": ["Group A: Vildagliptin plus metformin", "Group B: Glimepiride plus metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Amplitude of Glycemic Excursions (MAGE)", "timeFrame": "16 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients who have given written informed consent to participate in the study.\n2. Type 2 Diabetes Mellitus patients either Male or female from 18 - 75 years of age (both inclusive).\n3. Patients who are uncontrolled on metformin monotherapy for at least past 4 weeks (1000-1500 mg daily and HbA1c \\> 7.5 - 9%).\n4. Patients with HbA1C levels within the range \\> 7.5% - 9%. (If a past value is available within the last 12 weeks, it would be considered acceptable provided it was obtained after at least 4 weeks of metformin therapy 1000-1500 mg daily).\n\nExclusion Criteria:\n\n1. Age \\> 75 years ; BMI \\<22 or \\>40 kg/m2\n2. Patients who are on Insulin therapy at the time of study entry.\n3. Type 1 Diabetes Mellitus patients.\n4. Patients with severe renal (creatinine clearance \\< 50 ml/min) or hepatic impairment (including pre-treatment ALT or AST \\> 3 x ULN).\n\n   Creatinine clearance will be estimated from serum creatinine using Cockcroft-Gault formula (Cockcroft and Gault, 1976)\n5. Patients with contraindications as mentioned in the Summary of Product Characteristics (SPCs) for vildagliptin, metformin, glimepiride, vildagliptin plus metformin and glimiperide plus metformin.\n\nOther protocol defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Group A: Vildagliptin Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)."}, {"id": "FG001", "title": "Group B: Glimepiride Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "47"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Sponsor decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group A: Vildagliptin Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)."}, {"id": "BG001", "title": "Group B: Glimepiride Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "95"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.7", "spread": "11.86"}, {"groupId": "BG001", "value": "52.1", "spread": "9.29"}, {"groupId": "BG002", "value": "50.9", "spread": "10.68"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "36"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "59"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Amplitude of Glycemic Excursions (MAGE)", "populationDescription": "The study was prematurely terminated due to the unavailability of CGMS required for the assessment of the primary end point. The non-availability of CGMS severely affected participant recruitment. The primary outcome was not analyzed.", "reportingStatus": "POSTED", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Group A: Vildagliptin Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)."}, {"id": "OG001", "title": "Group B: Glimepiride Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Group A: Vildagliptin Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).", "seriousNumAffected": 0, "seriousNumAtRisk": 48, "otherNumAffected": 4, "otherNumAtRisk": 48}, {"id": "EG001", "title": "Group B: Glimepiride Plus Metformin", "description": "Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).", "seriousNumAffected": 1, "seriousNumAtRisk": 47, "otherNumAffected": 1, "otherNumAtRisk": 47}], "seriousEvents": [{"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "RESTLESSNESS", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "HYPERHIDROSIS", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}], "otherEvents": [{"term": "DIABETES MELLITUS", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis", "phone": "862-778-8200"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["India"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000077597", "term": "Vildagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1857", "name": "Vildagliptin", "asFound": "100%", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}